Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blood-borne assessment of stromal activation in esophageal adenocarcinoma to guide tocilizumab therapy
2020-002909-25Phase 2Active
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of tocilizumab in esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Pathological response (Mandard criteria). Started Oct 2020; status: active.
02
Drugs
tocilizumab
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2020-002909-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002909-25.